Literature DB >> 33624587

[Acute kidney injury in patients hospitalized with COVID-19 in Wuhan, China: a single-center retrospective observational study].

Guanhua Xiao1, Hongbin Hu2, Feng Wu2, Tong Sha2, Zhenhua Zeng2, Qiaobing Huang3, Haijun Li4, Jiafa Han4, Wenhong Song4, Zhongqing Chen2, Shumin Cai2.   

Abstract

OBJECTIVE: To assess the predictors and outcomes of acute kidney injury (AKI) among patients with coronavirus disease 2019 (COVID-19).
OBJECTIVE: This retrospective observational study was conducted among patients with a confirmed diagnosis of COVID-19 admitted to Hankou Hospital between January, 5 and March 8, 2020. We evaluated the association of AKI with the demographic and biochemical parameters and clinical outcomes of the patients using univariate regression analysis.
OBJECTIVE: Atotal of 287 COVID-19 patients, including 55 with AKI and 232 without AKI, were included in the analysis. Compared with the patients without AKI, the patients with AKI were older, predominantly male, and were more likely to have hypoxia and pre-existing hypertension and cerebrovascular diseases. The patients with AKI also had higher levels of white blood cells, D-dimer, aspartate aminotransferase, total bilirubin, creatine kinase, lactate dehydrogenase, procalcitonin, C-reactive protein, a higher prevalence of hyperkalemia, lower lymphocyte counts, and higher chest computed tomographic scores. The incidence of stage 1 AKI was 14.3% and that of stage 2 or 3 AKI was 4.9%. The patients with AKI had much higher mortality rate than those without AKI.
OBJECTIVE: AKI is an important complication of COVID-19. An older age, a male gender, multiple pre- existing comorbidities, lymphopenia, increased infection indicators, elevated D-dimer, and impaired heart and liver functions are all potential risk factors ofAKI. COVID- 19 patients with AKI that progresses into stages 2 or 3 AKI have a high mortality rate. Prevention of AKI and monitoring kidney function is critical in the care of COVID-19 patients.

Entities:  

Keywords:  acute kidney injury; coronavirus disease 2019; kidney function

Year:  2021        PMID: 33624587     DOI: 10.12122/j.issn.1673-4254.2021.02.01

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  13 in total

1.  Undersampling in action and at scale: application to the COVID-19 pandemic.

Authors:  Andreas Langousis; Alin Andrei Carsteanu
Journal:  Stoch Environ Res Risk Assess       Date:  2020-06-02       Impact factor: 3.379

2.  Effectiveness of convalescent plasma therapy in a patient with severe COVID-19-associated acute kidney injury.

Authors:  Zachary Z Brener; Adam Brenner
Journal:  Clin Nephrol Case Stud       Date:  2021-05-25

3.  Racial differences in cardiopulmonary outcomes of hospitalized COVID-19 patients with acute kidney injury.

Authors:  Obiora Egbuche; Temidayo Abe; Shirley I Nwokike; Opeyemi Jegede; Kenechukwu Mezue; Titilope Olanipekun; Ifeoma Onuorah; Melvin R Echols
Journal:  Rev Cardiovasc Med       Date:  2021-12-22       Impact factor: 4.430

4.  CSN COVID-19 Rapid Review Program: Management of Acute Kidney Injury.

Authors:  Edward G Clark; Swapnil Hiremath; Steven D Soroka; Ron Wald; Matthew A Weir
Journal:  Can J Kidney Health Dis       Date:  2020-07-15

5.  Damage to the waterworks: COVID-19 and the kidneys.

Authors:  Abdul Haadi; Talal Almas; Abdur Rahman Nabeel; Josiah Cy Chan; Abdulla Hussain Al-Awaid; Muhammad Ali Niaz; Gabriel Gurmail-Kaufmann
Journal:  Ann Med Surg (Lond)       Date:  2021-03-15

6.  Mortality and Severity in COVID-19 Patients on ACEIs and ARBs-A Systematic Review, Meta-Analysis, and Meta-Regression Analysis.

Authors:  Romil Singh; Sawai Singh Rathore; Hira Khan; Abhishek Bhurwal; Mack Sheraton; Prithwish Ghosh; Sohini Anand; Janaki Makadia; Fnu Ayesha; Kiran S Mahapure; Ishita Mehra; Aysun Tekin; Rahul Kashyap; Vikas Bansal
Journal:  Front Med (Lausanne)       Date:  2022-01-10

7.  Comparison of renin-angiotensin-aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes.

Authors:  Yihienew M Bezabih; Alemayehu Bezabih; Endalkachew Alamneh; Gregory M Peterson; Woldesellassie Bezabhe
Journal:  BMC Infect Dis       Date:  2021-06-05       Impact factor: 3.090

8.  Renin-angiotensin-aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis.

Authors:  Upinder Kaur; Sankha Shubhra Chakrabarti; Tejas K Patel
Journal:  Ther Adv Drug Saf       Date:  2021-05-14

Review 9.  COVID-19 and the kidney: what we think we know so far and what we don't.

Authors:  Samira S Farouk; Enrico Fiaccadori; Paolo Cravedi; Kirk N Campbell
Journal:  J Nephrol       Date:  2020-07-20       Impact factor: 3.902

Review 10.  Post-COVID-19 rehabilitation: a special look at chronic kidney disease patients.

Authors:  Heitor S Ribeiro; Amanda E Rodrigues; Jennifer Cantuária; Antônio Inda-Filho; Paul N Bennett
Journal:  Ren Replace Ther       Date:  2021-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.